Вопросы использования нестероидных противовоспалительных препаратов в ревматологической практике
- Авторы: Алексеева Л.И1
-
Учреждения:
- ГУ Институт ревматологии РАМН, Москва
- Выпуск: Том 11, № 2 (2009)
- Страницы: 95-100
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/92939
- ID: 92939
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаСписок литературы
- Burke A, Smyth E, Fitz Gerald G. Analgesic - ant - pyretic and anti - inflammatory agents and drugs employed in the treatment of gout. In: Brunton L, Lazo J, Parker K, eds. Goodman and Gilman\'s the pharmacological basis of therapeutics, 11th ed. New York: Mc Graw-Hill; 2005; 673–715.
- Gordon D.B., Dahl J.L., Miaskowski C et al. American pain society recommendations for improving the quality of acute and cancer pain management: American Pain Society quality of care task force. Arch Intern Med 2005; 165: 1574–80.
- Breivik H, Collett B, Ventafridda V et al. European survey of chronic non - cancer pain (CATI). Eur J Pain 2006; 10: 287–333.
- Lapane K.L., Spooner J.J., Pettiti D. The effect of nonsteroidal anti – inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care 2001; 7: 402–8.
- Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом. РМЖ. 2004; 12 (14): 844–7.
- Feldman M, Mc Mahon A.T. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti - inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43.
- Hernvann A, Bourely B, Le Maire V et al. Action of anti - inflammatory drugs on interleukin - 1 beta - mediated glucose uptake by synoviocytes. Eur J Pharmacol 1996; 314 (1–2): 193–6.
- Cicala C, IanaroA, Fiorucci S et al. NO-naproxen modulateds inflammation, nociception and downregulates T cell response in rat Freund`s adjuvant arthritis. Br J Pharmacol 2000; 130 (6): 1399–405.
- Pattern C, Bush K, Rioja I et al. Characterization of pristane - induce arthritis, a murine model of chronic disease: response to antirheumatic agents, expression of joint cytokines, and immunology. Arthritis Rheum 2004; 50 (10): 3334–45.
- Sanchez C, Mateus M.M., Defresne M.P. et al. Metabolism of human articular chondrocytes cultured in alginate beads. Long - term effects of interleukin - 1 beta and nonsteroidal anti - inflammatory drugs. J Rheumatol 2002; 29 (4): 772–82.
- Takahashi T, Uemura Y, Taguchi H et al. Cross talk between COX - 2 inhibitor and hyaluronic acid in osteoarthritis chondrocytes. Int J Mol Med 2004; 14 (2): 139–44.
- Maneiro E, Lopez-Armada M.J., Fernandez-Sueiro J.L. et al. Aceclofenac increases the synthesis of interleukin - 1 receptor antagonist and decreases the production of nitric oxide in human articular chojndrocytes. J Rheumatol 2001; 28 (12): 2692–9.
- Asano K, Matsuda T, Tanaka H et al. Suppression of matrix metalloproteinase production from synovial fibroblasts by meloxicam in vitro. J Pharm Pharmacol 2006; 58 (3): 359–66.
- Mathy-Hartert M, Deby-Dupond G.P.,Reginster J.Y. et al. Regulation by reactive oxygen species of interleukin-1 beta, nitric oxide and prostaglandin E(2) production by human chondrocytes. Osteoarthritis Cartilage 2002; 10 (7): 547–55.
- Насонов Е.Л. Нестероидные противовоспалительные препараты. М., 2000.
- Zhang W, Doherty M, Arden N et al. EULAR evidence - based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2005; 64: 669–81.
- Jordan K.M., Arden N.K., Doherty M et al. EULAR recommendations 2003: an evidence - based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutics trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43: 1905–15.
- Zhang W, Doherty M, Leeb B.F. et al. EULAR evidence - based recommendations for the management of hand osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 377–88.
- Towheed T.E., Judd M.J., Hochberg M.C., Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2003; 2: CD004257.
- Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34–45.
- American College of Rheumatology Subcommitte on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328–46.
- Solomon D.H., Karlson E.W., Rimm E.B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–7.
- Vasan R.S., Sullivan L.M., Roubenoff R et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation 2003; 107: 1486–91.
- Mc Gettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006; 296: 1633–44.
- Antman E.M., Bennett J.S., Daugherty A et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 1634–42.
- White W.B., West C.R., Borer J.S. et al. Risk of cardiovascular events in patients receiving celecoxib: a meta - analysis of randomized clinical trials. Am J Cardiology 2007; 99: 91–8.
- Singh G, Lanes S, Triadafilopoulos S. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J Med 2004; 117: 100–6.
- Altman R, Luciardi H, Muntaner J et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase - 2 inhibitor, in acute coronary syndromes without ST-segment elevation. Circulation 2002; 106: 191–5.
- Peura D.A. Prevention of nonsteroidal antiinflammatory drug - associated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117 (suppl. 5A): S63–71.
- Lanas A, Perez-Aisa M.A., Feu F et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100: 1685–93.
- Wilcox C.M., Allison J, Benzuly K et al. Consensus development conference on the use of nonsteroidal anti - inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006; 4: 1082–9.
- Hawkey C, Kahan A, Stenbruck K et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large - scale International Study Safety Assessment. Br J Rheumat 1998; 37: 1142–7.
- Dequerker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of selective cyclooxyenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946–51.
- Мазуров В.И., Беляев И.Б., Онущенко И.А. Опыт применения мелоксикама у больных анкилозирующим спондилоартритом. Клин. мед. 2001; 5: 53–5.
- Каратеев А.Е. Гастродуоденальные осложнения на фоне приема мелоксикама в реальной клинической практике. Научно - практ. ревматол. 2006; 1б: 28–33.
- Шостак Н.А., Аксенова А.В., Шеметов Д.А., Аринина Е.Е. Опыт применения мовалиса при синдроме болей в нижней части спины (LBP). Тер. архив. 1999; 11: 50–2.
- Schoenfeld P. Gastrointestinal safety profile of meloxicam: a methaanalysis and systematic review of randomizes controlled trials. Am J Med 1999; 107 (6A): 48S–54S.
- Rostom A, Goldkind L, Laine L. Nonsteroidal antiinflam - matory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005; 3: 489–98.
- Prieto Garcia А. Nabumetone and Meloxicam Well Tolerated in NSAID - Intolerant Subjects. J Allergy Clin Immunol 2007; 119: 960–4.
- Clinical Pharmacology Online. Gold standard, inc., 2007. Available from http://proxy.library.siue.edu:2145/Default.aspx. Accessed September 7, 2007.
- Herndon C.M., Hutchison R.W., Berdine H.J. et al. Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs. Pharmacotherapy 2008; 28 (6): 788–805.
Дополнительные файлы
